Welcome to our dedicated page for Immunitybio SEC filings (Ticker: IBRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The ImmunityBio, Inc. (NASDAQ: IBRX) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, including annual reports, quarterly reports, and current reports on Form 8‑K. As a commercial-stage biotechnology issuer focused on IL‑15–based immunotherapies and cell therapies, ImmunityBio uses these filings to report financial performance, capital structure changes, governance matters, and material agreements related to its ANKTIVA‑centered portfolio.
Annual reports (Form 10‑K) and quarterly reports (Form 10‑Q) detail product revenue from ANKTIVA, research and development spending on programs such as QUILT‑3.032 in non‑muscle invasive bladder cancer and QUILT‑2.023/3.055 in non‑small cell lung cancer, and broader risk factors associated with developing and commercializing biologic therapies. These filings also summarize segment information, which the company describes as including the United States and Europe, and discuss liquidity, debt obligations, and equity plans.
Current reports (Form 8‑K) capture specific material events. Recent 8‑Ks disclose an at‑the‑market offering program amendment authorizing additional common stock sales under a shelf registration statement, a registered direct offering of common shares and warrants, adoption of the 2025 Equity Incentive Plan, and the appointment of independent directors. Other 8‑Ks reference earnings press releases that report net product revenue growth for ANKTIVA and changes in cash, cash equivalents, and marketable securities.
Investors interested in capital markets activity can review filings describing increases in authorized common stock, revenue interest liabilities, and equity incentive structures. Governance‑focused readers can examine disclosures on board composition, director compensation policies, and the preliminary approval of a settlement of stockholder derivative actions that includes corporate governance reforms.
Stock Titan enhances these filings with AI‑powered summaries that explain key points in accessible language. Instead of parsing lengthy 10‑K or 10‑Q documents line by line, users can see concise overviews of ImmunityBio’s revenue trends, R&D priorities, financing arrangements, and risk disclosures, then drill down into the original SEC documents when more detail is needed.
For those tracking IBRX insider and executive activity, forms such as Form 4 and proxy‑related materials (when available) provide insight into equity awards, option grants, and ownership changes, complementing the broader financial and operational picture presented in periodic reports.
ImmunityBio, Inc. director, CEO and President Richard Adcock reported equity award activity involving restricted stock units (RSUs) and common stock. On February 22, 2026, 152,439 RSUs were exercised or converted into 152,439 shares of common stock at a price of $0.00 per share, reflecting vesting of a prior RSU grant.
In a related tax-withholding transaction, 77,560 shares of common stock were disposed of at $8.70 per share to cover tax obligations associated with the RSU vesting, rather than an open-market sale. Following these transactions, Adcock directly held 560,344 shares of ImmunityBio common stock. Footnotes explain that each RSU represents a right to receive one share of common stock and outline a three-year vesting schedule that began on February 22, 2024, conditioned on continued service.
ImmunityBio director Barry J. Simon reported a mix of stock sales and equity awards for ImmunityBio, Inc. common stock. He sold 165,000 shares on February 23, 2026 in open-market transactions at a weighted average price of $10.2491 per share under a Rule 10b5-1 trading plan, and sold another 10,000 shares on February 20, 2026 at $9.25 per share. On February 22, 2026, restricted stock units representing 15,243 shares vested and were converted into common stock at no cost, with 6,026 shares withheld at $8.70 per share to cover taxes. After these transactions, he directly owned 2,925,821 shares of ImmunityBio common stock.
ImmunityBio, Inc. outlines how it is transitioning into a commercial-stage immunotherapy company built around its IL-15 receptor superagonist ANKTIVA. Net product revenue reached approximately $113 million in 2025, with about 700% year-over-year growth and Q4 2025 revenue of $38.3 million, supported by lives covered exceeding 240 million in the U.S.
ANKTIVA with BCG is approved for BCG-unresponsive NMIBC CIS in the U.S., UK and Saudi Arabia and has conditional EU authorization, while Saudi Arabia granted conditional approval with checkpoint inhibitors for metastatic NSCLC. The company is running an extensive pipeline of trials across bladder, lung, pancreatic, brain and hematologic cancers, as well as infectious diseases, and has received FDA RMAT designation and multiple expanded access authorizations tied to lymphopenia reversal.
ImmunityBio, Inc. notice: a Form 144 discloses a proposed sale of 25,000 common shares on 02/23/2026 related to an exercise of stock options. The filing records prior 10b5-1 sales by Christobel Selecky of 25,000 shares on 01/20/2026 for $187,650 and 50,000 shares on 01/16/2026 for $250,000.
ImmunityBio reported full-year 2025 results highlighting explosive ANKTIVA growth alongside continued losses. Net product revenue from ANKTIVA reached $113 million, an approximately 700% year-over-year increase, with Q4 2025 net product revenue of $38.3 million and unit sales up about 750% versus 2024.
Regulatory approvals now cover BCG-unresponsive bladder cancer across four jurisdictions and 33 countries, and Saudi Arabia granted conditional accelerated approval for metastatic non-small cell lung cancer, with launch planned within 60 days of approval. Despite this momentum, the company posted a 2025 net loss attributable to common stockholders of $351.4 million, improved from $413.6 million in 2024, and ended the year with $242.8 million in cash, cash equivalents, and marketable securities against total liabilities of $1.0 billion.
ImmunityBio reported that the European Commission has granted conditional marketing authorization for ANKTIVA (nogapendekin alfa inbakicept) plus BCG to treat adults with BCG‑unresponsive non‑muscle invasive bladder cancer carcinoma in situ, with or without papillary tumors.
This decision makes ANKTIVA the first immunotherapy authorized in Europe for this high‑risk bladder cancer setting and extends availability across all 27 EU member states plus Iceland, Norway, and Liechtenstein, bringing total country coverage to 33. Approval is based on the QUILT‑3.032 trial, which showed a 71% complete response rate, a median complete response duration of 26.6 months, and cystectomy‑free survival among responders of 96% at 12 months and 84% at 36 months.
The authorization is conditional and requires ImmunityBio to submit long‑term safety and efficacy data and renew the authorization annually, while the company pursues pricing, reimbursement, and patient access across Europe.
ImmunityBio, Inc. insider activity: Patrick Soon-Shiong and affiliated entities reported equity award vesting and related share movements. On February 10, 2026, 274,122 restricted stock units were converted into an equal number of ImmunityBio common shares at an exercise price of $0.00. To cover tax obligations on this vesting, 118,560 common shares were withheld at a price of $6.93 per share. Following these transactions, Soon-Shiong directly held 29,701,752 common shares. The filing also lists very large indirect holdings through entities such as Nant Capital, Cambridge Equities, NantBio, California Capital Equity, the Chan Soon-Shiong Family Foundation, NantWorks, NantMobile and NantCancerStemCell, over which he is described as having varying degrees of voting and dispositive power.
ImmunityBio, Inc. Chief Financial Officer David C. Sachs reported RSU vesting and related share withholding. On February 10, 2026, 82,236 restricted stock units converted into 82,236 shares of common stock at an exercise price of $0, increasing his directly held common stock to 322,818 shares.
On the same date, 42,643 common shares were disposed of at $6.93 per share to cover tax obligations tied to the RSU vesting, leaving him with 280,175 common shares held directly after these transactions. Following the vesting, he also held 164,474 RSUs directly.
ImmunityBio, Inc.’s Chief Accounting Officer, Regan J. Lauer, reported RSU vesting and related share movements. On February 10, 2026, 5,482 restricted stock units were converted into 5,482 shares of common stock at an exercise price of $0, increasing directly held common shares to 115,740.
On the same date, 2,257 common shares were withheld at $6.93 per share to cover tax obligations tied to the vesting, leaving 113,483 common shares held directly after the withholding. Following these transactions, Lauer also directly held 10,965 restricted stock units, which vest over three years starting from a February 10, 2025 commencement date.
ImmunityBio, Inc. executive Richard Adcock, the CEO and President, reported equity compensation activity involving restricted stock units (RSUs) and common stock. On February 10, 2026, 274,122 RSUs were converted into the same number of common shares at an exercise price of $0, reflecting vesting of a prior RSU grant.
To cover tax obligations from this vesting, 140,048 common shares were withheld and disposed of at a price of $6.93 per share. After these transactions, Adcock beneficially owned 485,465 shares of ImmunityBio common stock directly, along with 548,246 RSUs that remain outstanding as derivative securities. The RSU award vests over three years from a vesting commencement date of February 10, 2025, contingent on continued service.